Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.86 |
| ▸ | MAPT | P10636 | 3/20 | 0.80 |
| ▸ | NPC1 | O15118 | 3/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.76 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.76 |
| ▸ | BCHE | P06276 | 2/20 | 0.71 |
| ▸ | MAOB | P27338 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.68 |
| ▸ | JUN | P05412 | 1/20 | 0.68 |
| ▸ | PDE4A | P27815 | 1/20 | 0.68 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.68 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7180829 | 1.00 | ABCG2 (0.86) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7185006 | 0.91 | ABCG2 (0.97) | ABCG2MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL7185011 | 0.91 | ABCG2 (0.97) | ABCG2MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL7188219 | 0.90 | ABCG2 (0.79) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7188211 | 0.90 | ABCG2 (0.79) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7188106 | 0.89 | MAPT (1.00) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7188111 | 0.89 | MAPT (1.00) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30307319 | 0.87 | ABCG2 (0.89) | ABCG2MAPTNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6352780 | 0.87 | ABCG2 (0.89) | ABCG2MAPTRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL6352783 | 0.87 | ABCG2 (0.89) | ABCG2MAPTRAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | STATENS SERUM INSTITUTE (DK) | 2003-04-03 | — | — | US | claimed |
| EP-0996432-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUMINSTITUT (DK) | 2000-05-03 | — | — | EP | claimed |
| WO-1999000114-A2 | BIOLOGICALLY ACTIVE 1,3-BIS-AROMATIC-PROP-2-EN-1-ONES, 1,3-BIS-AROMATIC-PROPAN-1-ONES, AND 1,3-BIS-AROMATIC-PROP-2-YN-1-ONES | STATENS SERUM INSTITUT (DK) | 1999-01-07 | — | — | WO | claimed |
| US-6603046-B1 | The invention is drawn to novel bis-aromatic a, beta -unsaturated ketones. The compounds are useful in the treatment and prophylaxis of diseases caused by parasites or bacteria. | LICA PHARMACEUTICALS A/S (DK) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065039-A1 | Biologically active 1,3-bis-aromatic-prop-2-en-1-ones, 1,3-bis-aromatic-propan-1-ones, and 1,3-bis-aromatic-prop-2-yn-1-ones | AKR1C3, AKR1C1, AKR1A1 | ABCG2 1177/4885MAPT 3817/4885NPC1 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.